Загрузка...
Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US
BACKGROUND: Dalfampridine extended release tablets (dalfampridine-ER; prolonged-, modified, or sustained-release fampridine in some countries) were approved in the US to improve walking in patients with multiple sclerosis, as demonstrated by improvement in walking speed. Postmarketing safety experie...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3647381/ https://ncbi.nlm.nih.gov/pubmed/23662056 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S41596 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|